Vandetanib Therapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of medullary thyroid cancer (MTC) in patients with Rearranged during Transfection (RET) mutation positive, unresectable locally advanced or metastatic disease. | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::RET | Medullary Thyroid Cancer | Vandetanib |